Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the expanding adoption of subcutaneous drug ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...

U.S. company Halozyme Therapeutics, regarded as a competitor to Korea's bio corporations Alteogen, will acquire Elektrofi, which has subcutaneous injection drug delivery technology, for up to $900 ...

Earlier this week, Halozyme Therapeutics’ subsidiary Halozyme Hypercon announced a global exclusive collaboration and license agreement granting Vertex Pharmaceuticals access to its Hypercon ...

(Reuters) -Halozyme Therapeutics said on Wednesday it has agreed to acquire privately held Elektrofi in a deal worth up to $900 million to expand its drug delivery portfolio, sending its shares up 3% ...

Halozyme has previously licensed the Hypercon technology to other pharmaceutical companies including Janssen, Eli Lilly, and argenx. The company is also known for its ENHANZE drug delivery technology, ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued biotech stocks to buy right now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on April 7 that its wholly-owned ...

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced ...

Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics for the development of ORKA-001 using Hypercon Technology. Oruka has licensed the Halozyme ...